Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Maximum Androgen Blockade in Metastatic Prostate Cancer
NCT00255268Phase 4Withdrawn
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of goserelin, bicalutamide in prostate cancer (PCa), sponsored by AstraZeneca. Planned start Aug 2004; status: withdrawn.
02
Drugs
goserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00255268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255268.